Kiniksa Pharmaceuticals Ltd

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kiniksa Pharmaceuticals reports robust Q2 growth and strategic initiatives

Kiniksa Pharmaceuticals delivered a strong Q2 performance with significant revenue growth driven by ARCALYST sales and strategic initiatives. The company's focus on disease awareness and patient base expansion bodes well for future growth.
While challenges such as managing expenses and addressing operational complexities persist, Kiniksa's solid financial position and market opportunities position it favorably for sustained growth and value creation.
Overall, Kiniksa Pharmaceuticals' Q2 earnings call highlights a mix of strong performance, strategic strengths, operational challenges, and growth opportunities, signaling a dynamic and evolving landscape for the company.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. It engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. The company was founded on April 9, 2024 and is headquartered in London, United Kingdom.

Canopy Growth

Paycom Software

A much-needed vote of confidence lifted an entire industry.

Why Canopy Growth, Kiniksa Pharmaceuticals, and Paycom Software Jumped Today

HAMILTON, Bermuda, Nov.  20, 2019  (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd.  (Nasdaq: KNSA) announced today that it will present at the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4th, 2019 at 3:30 p.m. Eastern Time at the Four Seasons Hotel in Boston, MA.

Kiniksa Pharmaceuticals to Present at the 2nd Annual Evercore ISI HealthCONx Conference

The company's lead drug candidate earned Breakthrough Therapy designation from American regulators.

Here's Why Kiniksa Pharmaceuticals Rose as Much as 36.7% Today

Kiniksa Pharmaceuticals Ltd. (NASDAQ: KNSA) shares jumped on Wednesday after the firm announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis.

Why This FDA Breakthrough Is a Big Deal for Recurrent Pericarditis Patients

HAMILTON, Bermuda, Nov.  20, 2019  (GLOBE NEWSWIRE) --  Kiniksa Pharmaceuticals, Ltd.  (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for rilonacept for the treatment of recurrent pericarditis. Rilonacept is a weekly, subcutaneously-injected, recombinant fusion protein that blocks IL-1α and IL-1β signaling.

Kiniksa Announces Breakthrough Therapy Designation for Rilonacept for the Treatment of Recurrent Pericarditis

–  Clinical data readouts expected throughout 2020 for rilonacept, mavrilimumab, KPL-716 and KPL-404 –  – Operating plan funded into 2H 2021; no current plan to raise additional capital prior to delivering clinical data readouts  –  – Final rilonacept Phase 2 data to be presented at the American Heart Association Scientific Sessions 2019 –  –  First subject dosed in first-in-human trial of KPL-404 – 

Kiniksa Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate and Pipeline Activity

G1 Therapeutics

Regeneron Pharmaceuticals

Some investors think the market's been too hard on these drugmakers.

Are These 3 Beaten-Down Biotech Stocks Bargains Now?

Kiniksa Pharmaceuticals, Ltd. (KNSA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Kiniksa Pharmaceuticals Enters Oversold Territory

Data reinforce the scientific evidence supporting the potential treatment of chronic pruritic diseases through OSMRβ inhibition Data reinforce the scientific evidence supporting the potential treatment of chronic pruritic diseases through OSMRβ inhibition

Kiniksa Presents Preclinical Data Supporting KPL-716 Clinical Development at the 49th Annual Meeting of the European Society of Dermatological Research

HAMILTON, Bermuda, Aug.  19, 2019  (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients with significant unmet medical need, today announced that it will present final data from an open-label, multicenter Phase 2 clinical trial of rilonacept in different pericarditis populations at the American Heart Association (AHA) Scientific Sessions 2019 at the Pennsylvania Convention Center in Philadelphia, PA. Three other research collaborations will be presented to address pericarditis, its burden and its underlying mechanism.

Kiniksa to Present Rilonacept Final Phase 2 Clinical Data at the American Heart Association Scientific Sessions 2019

News for Kiniksa Pharmaceuticals Ltd Stock (KNSA)